<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04173455</url>
  </required_header>
  <id_info>
    <org_study_id>HZ-A-018-001</org_study_id>
    <nct_id>NCT04173455</nct_id>
  </id_info>
  <brief_title>Study of the Safety, Tolerability and Pharmacokinetics of HZ-A-018 in Patients With B Cell Lymphoma</brief_title>
  <official_title>Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of Bruton Tyrosine Kinase (BTK) Inhibitor HZ-A-018 in Patients With B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hangzhou HeZheng Pharmaceutical Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital of Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the safety, tolerability, pharmacokinetics and RP2D
      (Recommended Phase II Dose) of orally administered HZ-A-018 in patients with B cell lymphoma
      who have at least failed or relapsed after first-line treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2019</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity assessment for each patient</measure>
    <time_frame>At the end of the first 28 day cycle</time_frame>
    <description>The &quot;3+3&quot; design will be applied in the dose-escalation part.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>The &quot;3+3&quot; design will be applied in the dose-escalation part.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Adverse events at each visit with the NCI CTCAE v5.0 used as a guide for the grading of severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to t (AUC0~t)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to infinity (AUC0~∞)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (t1/2)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BTK (Brutons tyrosine kinase) occupancy in PBMCs(peripheral blood mononuclear cells)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The proportion of CR (complete response) and PR (partial response).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Duration of response is defined as the time from the date of first occurrence of CR (complete response) or PR (partial response) to the date of the first documented PD (progressive disease) or death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Lymphoma, B-Cell</condition>
  <arm_group>
    <arm_group_label>HZ-A-018</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the dose-escalation part, the &quot;3+3&quot; design will be applied. If the subject does not have a DLT during the first 28-day cycle, those who with stable or remission of disease may continue to receive treatment until disease progression, intolerable toxicity or the subject no longer benefits.
In the dose-expansion part, HZ-A-018 will be administered for several 28-day cycles until disease progression, intolerable toxicity or the subject no longer benefits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HZ-A-018</intervention_name>
    <description>In the dose-escalation part, subjects will be assigned to five cohorts with increaing dose level to determine DLT and MTD during the first 28-day cycle.
In the expansion part, subjects will be assigned to two fixed dose corhort.</description>
    <arm_group_label>HZ-A-018</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women and men between 18 and 75 years old, voluntarily signed a informed consent.

          -  Body weight ≥ 45 kg.

          -  ECOG (Eastern Cooperative Oncology Group) performance status of 0~1.

          -  Life expectancy (in the opinion of the investigator) of ≥ 4 months.

          -  Patients with histologically or cytologically confirmed mature B-cell lymphoma
             according to 2017 WHO (World Health Organization) classification, including chronic
             lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma
             (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), Waldenström's
             Macroglobulinemia (WM) and diffuse large B-cell lymphoma (DLBCL); previous treatment
             for DLBCL patients must include Rituxan (CD20 monoclonal antibody) and
             anthracyclines-based therapy and meet one of the following criteria: 1）complete
             response was not achieved after previous second line therapy; 2) disease progression
             occurred during any of previous treatment; 3) the duration of stable disease was ≤ 6
             months; 4) Disease progression or recurrence occurred within 12 months after
             autologous hematopoietic stem cell transplantation; CLL and other indolent B-cell NHL
             patients must meet one of the following criteria: at least failure to respond to first
             line therapy (SD or PD after treatment with Rituxan-based and alkylating agents or
             anthracyclines therapy), any response (CR or PR) and progression after stable disease.

          -  Measurable disease for SLL, MCL, FL, DLBCL and MZL: lymph node lesions＞1.5 cm diameter
             in at least one dimension or any of external node lesions ＞1.0 cm diameter in at least
             one dimension; for CLL, peripheral blood monoclonal lymphocytes ≥ 5.0×109/L; for WM,
             IgM﹥2×ULN (upper limit of normal).

          -  Any non-hematologic toxicity associated with prior treatment should recover to grade ≤
             1 (according to NCI CTCAE version 5.0).

          -  Adequate hematological function (no blood transfusion, no use of G-CSF (G-Colony
             stimulating factor) and no drug correction within 14 days of screening): absolute
             neutrophil count (ANC) ≥ 0.75 × 109 /L (≥ 0.5×109/L if presence of bone marrow
             infiltration); platelet count ≥ 50 × 109/L; Hgb ≥ 8.0 g/dL (≥7.0 g/dL if presence of
             bone marrow infiltration for WM and CLL).

          -  Adequate renal function: serum creatinine ≤ 1.5 × ULN or estimated creatinine
             clearance ≥ 60 mL/min (Male: Cr (mL/min) = (140- age) × weight (kg) /72× serum
             creatinine concentration (mg/dl); Female: Cr (ml/min) = (140- age) × weight (kg) /85×
             serum creatinine concentration (mg/dl)).

          -  Adequate liver function: total serum bilirubin ≤ 1.5 x ULN (≤3.0×ULN if presence of
             liver metastasis); AST and ALT ≤ 2.5 x ULN (≤5.0×ULN if presence of liver metastasis).

          -  Female of childbearing age and males subjects with fertility must practice at least
             one of the following effective contraception methods throughout the study and within
             90 days of discontinuing study drug: total abstinence from sexual intercourse,
             physical contraception, or hormonal contraceptive initiated at least 3 months prior to
             first dose of study drug.

          -  Male subjects must not donate sperm from initial study drug administration, until 90
             days after drug discontinuation.

          -  Ability to swallow oral capsules without difficulty.

          -  Willing to follow visit schedules, drug administration schedules, laboratory tests and
             other test procedures.

        Exclusion Criteria:

          -  Prior BTK inhibitor treatment.

          -  Infiltration of CNS (central nervous system) by lymphoma.

          -  Prior organ transplantation or allogeneic hematopoietic stem cell transplantation.

          -  History of other active malignancies, with exception of basal cell carcinoma of skin,
             squamous cell carcinoma of skin, cervical carcinoma in situ, or other carcinoma in
             situ with curative therapy and no recurrence within 5 years.

          -  Uncontrolled systemic infection or infection requiring intravenously anti-microbial
             therapy.

          -  Major surgery or severe trauma within 4 weeks before signing the informed consent.

          -  Any of the following conditions occurred within the past 6 months: significant cardiac
             diseases, such as congestive heart failure (NYHA III or IV heart failure), myocardial
             infarction, and unstable angina pectoris; significant ECG abnormalities, such as
             atrial fibrillation of any grade, grade II atrioventricular block or grade III
             atrioventricular block or QTc (F) &gt; 470 msec (female) or &gt; 450 msec (male); other
             arrhythmias that require treatment.

          -  Active renal, neurological/psychiatric, liver or endocrine disease, in the opinion of
             the investigator, would adversely impact on his/her participating in the study.

          -  Inability to comply with study procedures.

          -  Stroke or cerebral hemorrhage occurred within 6 months prior to the first dose of the
             study drug.

          -  Uncontrolled hypertension, in the opinion of the investigator.

          -  Previous or active pulmonary fibrosis, interstitial pneumonia, pneumoconiosis,
             radioactive pneumonia, etc.

          -  Active hepatitis B or C infection (HBV: HBV-DNA ≥1000 IU/mL; hcv: HCV RNA positive
             with abnormal liver function) or human immunodeficiency virus (HIV) infection or
             syphilis.

          -  Active enteritidis , chronic diarrhea, known diverticulosis, or prior gastrectomy or
             gastric banding, or other conditions that affect absorption.

          -  Concurrent use of a strong CYP3A4/5 inhibitor (ketoconazole, itraconazole,
             voriconazole, posaconazole, talimycin, and clarithromycin) or inducers (carbamazepine,
             rifampicin, phenytoin sodium, etc.) during the study.

          -  Concurrent use of warfarin or vitamin K antagonists or anticoagulation therapies, or
             having bleeding tendency or coagulation disorder, within 4 weeks prior to signing the
             informed consent or during the study.

          -  Treatment with anti-tumor therapy (including chemotherapy, radiotherapy,
             immunotherapy, targeted therapy, traditional Chinese medicine or other clinical
             research therapy) within 4 weeks prior to signing the informed consent; anti-tumor
             treatment with steroid hormone (dose equivalent to prednisone &gt; 20 mg) within 7 days
             prior to signing the informed consent.

          -  Pregnant, breast-feeding or intending to have children with their partners during the
             study and within 3 months after discontinuation of the study.

          -  Participating in another clinical trial and taking the drug within 4 weeks prior to
             signing the informed consent.

          -  In the opinion of the investigator, other factors that may cause subjects to be forced
             to terminate the study, such as other serious diseases, serious laboratory
             abnormalities, and other factors that may affect subjects' safety or test data and
             blood sample collection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianzhong Shentu</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianzhong Shentu, MD</last_name>
    <phone>+86057187236560</phone>
    <email>stjz@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>First Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianzhong Shentu, MD</last_name>
      <phone>+86057187236537</phone>
      <email>stjz@zju.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Wenbin Qian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianzhong Shentu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Zhejiang University</investigator_affiliation>
    <investigator_full_name>shentu jianzhong</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

